MedTrace Logo

Abscopal Effect from the Low-dose Radiotherapy in Polymetastatic Cancer Patients Receiving Stereotactic Radiotherapy

NCT05733156 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2024-12-10

No results posted yet for this study

Summary

Recently, MD Anderson Cancer Center reported the phase II trial to investigate high-dose radiotherapy (HDRT, 20-70 Gy) and low-dose radiotherapy (LDRT, 1-10 Gy) for metastatic cancer patients who had undergone immunotherapy. HDRT or HDRT+LDRT was conducted in two respective groups and the treatment group was determined according to the disease status of participants, not randomization. Immunotherapy was maintained in this clinical study. Therefore, we aim to investigate this abscopal effect from adding LDRT to HDRT, irrespective of previous immunotherapy, in this multicenter, single-arm study.

Conditions

  • Neoplasms
  • Secondary Malignant Neoplasm

Interventions

RADIATION

SBRT + LDRT

Stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently. SBRT is administered three times, at intervals of 1-2 days, and patients are treated with LDRT along with SBRT. LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.

Sponsors & Collaborators

  • SMG-SNU Boramae Medical Center

    collaborator OTHER

  • Catholic University of Korea, St. Vincent Hospital

    collaborator UNKNOWN

  • Seoul National University Hospital

    collaborator OTHER

  • Chungnam National University Hospital

    collaborator OTHER

  • Soonchunhyang University Hospital

    lead OTHER

Principal Investigators

  • Ah Ram Chang, MD, PhD · Soonchunhayng Universtiy Seoul Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-03
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05733156 on ClinicalTrials.gov